Allograft vasculopathy after heart transplantation: impact of time related course, severity, and progression on prognosis during long-term follow-up

被引:0
作者
Pethig, K [1 ]
Besser, K [1 ]
Heublein, B [1 ]
Wahlers, T [1 ]
Harringer, W [1 ]
Haverich, A [1 ]
机构
[1] Hannover Med Sch, Zentrum Chirurg, Abt Thorax Herz & Gefasschirurg, D-30623 Hannover, Germany
来源
ZEITSCHRIFT FUR KARDIOLOGIE | 1999年 / 88卷 / 07期
关键词
heart transplantation; cardiac allograft vasculopathy; prevalence; progression; prognosis;
D O I
10.1007/s003920050314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite considerable progress in the knowledge about pathophysiology of cardiac allograft vascular disease (CAVD), only few systematic studies are available, characterizing the natural course during long-term follow-up after heart transplantation (HTX). Therefore, we analyzed in 354 heart transplant recipients (305 male, 45.9 +/- 11.2 years, mean observation period 5.8 +/- 3.0 years, range 0.9-12.4 years) the results of 1129 coronary angiograms under the aspects of development, severity, localization, and progression of disease related to the prognosis of patients. As expected an increasing prevalence was found over time with a luminal obstruction greater than or equal to 30 % in 83 % of all patients more than 10 years after HTX. Coronary artery stenosis (greater than or equal to 50 %) at initial diagnosis was predominantly localized in the LAD (46 %) followed by RCX (31%)and RCA (23 %). Angiographic risk profiles with an impaired prognosis could be identified in the form of an early development (< 4 years post HTX) of disease (p = 0.03), luminal obstruction > 50 % (p = 0.001), and multivessel appearance at first diagnosis (p = 0.02) as well as in progressive forms of CAVD (p = 0.001). Summarizing, CAVD is a frequent finding in HTX recipients. Especially in patients with early onset, progressive, and advanced stages of disease it represents a prognostically limiting complication following HTX. Identification of the natural course is of major importance defining the need and efficacy of future palliative therapeutical approaches.
引用
收藏
页码:498 / 506
页数:9
相关论文
共 35 条
[21]   INTRAINDIVIDUAL VARIABILITY OF CARDIAC ALLOGRAFT VASCULOPATHY AS ASSESSED BY INTRAVASCULAR ULTRASOUND [J].
KLAUSS, V ;
MUDRA, H ;
UBERFUHR, P ;
THEISEN, K .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (07) :463-466
[22]   EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION [J].
KOBASHIGAWA, JA ;
KATZNELSON, S ;
LAKS, H ;
JOHNSON, JA ;
YEATMAN, L ;
WANG, XM ;
CHIA, D ;
TERASAKI, PI ;
SABAD, A ;
COGERT, GA ;
TROSIAN, K ;
HAMILTON, MA ;
MORIGUCHI, JD ;
KAWATA, N ;
HAGE, A ;
DRINKWATER, DC ;
STEVENSON, LW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) :621-627
[23]  
Lim TT, 1997, CIRCULATION, V95, P855
[24]  
Park S J, 1996, Cardiovasc Surg, V4, P37, DOI 10.1016/0967-2109(96)83781-1
[25]   Impact of plaque burden on compensatory enlargement of coronary arteries in cardiac allograft vasculopathy [J].
Pethig, K ;
Heublein, B ;
Wahlers, T .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (01) :89-&
[26]   Mechanism of luminal narrowing in cardiac allograft vasculopathy: Inadequate vascular remodeling rather than intimal hyperplasia is the major predictor of coronary artery stenosis [J].
Pethig, K ;
Heublein, B ;
Wahlers, T ;
Haverich, A .
AMERICAN HEART JOURNAL, 1998, 135 (04) :628-633
[27]  
Pethig K, 1998, CIRCULATION, V98, P751
[28]  
PETHIG K, 1998, TX MED, V10, P85
[29]  
PETHIG K, 1998, EUR HEART J, V19, pS254
[30]  
PETHIG K, 1997, Z KARDIOL, V86, P98